Vallon Pharmaceuticals VLON

$ 0.43 -6.47%

Quarterly report 2024-Q3
added 11-14-2024

Vallon Pharmaceuticals Financial Statements 2011-2024 | VLON

Annual Financial Statements Vallon Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	198 K	55.5 K	26.2 M	-	-	-	-	-	-	-	-	-	-
Shares	462 K	129 K	6.54 M	-	-	-	-	-	-	-	-	-	-
Historical Prices	0.43	0.43	4.88	-	-	-	-	-	-	-	-	-	-
Net Income	-13 M	-3.22 M	-9.3 M	-4.82 M	-3.46 M	-4.31 M	-	-	-	-	-	-	-
Revenue	-	-	-	100 K	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	100	-	-	-	-	-	-	-	-	-
Operating Income	-11.4 M	-2.24 M	-9.26 M	-4.79 M	-	-	-	-	-	-	-	-	-
Interest Expense	250 K	-	61 K	-	-	-	-	-	-	-	-	-	-
EBITDA	-11.4 M	-2.24 M	-9.26 M	-4.71 M	-3.14 M	-4.31 M	-	-	-	-	-	-	-
Operating Expenses	11.4 M	2.24 M	9.26 M	4.89 M	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	8.16 M	2 M	4.07 M	1.18 M	1.27 M	801 K	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Vallon Pharmaceuticals

	2024-Q3	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	3.16 M	49.7 K	32.5 K	2.42 M	449 K	1 M	896 K	851 K	227 K	6.81 M	6.81 M	6.81 M	5.71 M	4.51 M	4.51 M	4.51 M	4.51 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-2.12 M	-	-2.14 M	-6.75 M	-2.15 M	-	-351 K	-295 K	-302 K	-	-1.26 M	-2.31 M	-2.64 M	-	-1.04 M	-1.15 M	-1.16 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-2.13 M	-	-2.44 M	-5.93 M	-2.35 M	-	-186 K	-189 K	-2.63 M	-	-1.25 M	-2.31 M	-2.6 M	-	-1.03 M	-1.14 M	-1.16 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	250 K	-	16 K	-	2 K	-	-1 K	-	-4 K	-2 K	-8 K	-	-12 K	-12 K	-2 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-2.35 M	-	-186 K	-189 K	-2.63 M	-	-1.25 M	-2.31 M	-2.6 M	-	-1.03 M	-1.14 M	-1.16 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	2.13 M	-	2.44 M	5.93 M	2.35 M	-	186 K	189 K	2.63 M	-	1.25 M	2.31 M	2.6 M	-	1.03 M	1.14 M	1.26 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	1 M	-	1.25 M	5.05 M	2.47 M	-	123 K	130 K	1.36 M	-	1.04 M	1.11 M	830 K	-	300 K	327 K	375 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency